Burcon NutraScience Reports Q4

On Wednesday, Burcon NutraScience (TSX: BU ) discussed fourth-quarter financial results during its earnings call.

The full transcript is provided below.

This content is powered APIs.

For comprehensive financial data and transcripts, visit View the webcast at Summary Burcon NutraScience Corporation reported fiscal 2026 revenues of $2.3 million, marking a nearly six-fold increase from the previous year, with consistent quarter-over-quarter growth.

The company highlighted its proven technology platform for plant-based proteins, emphasizing its commercial success and repeat customer sales across multiple protein types such as pea, canola, and fava.

Burcon is focused on scaling production and expanding its customer base, with more than 200 active projects and over 30 active buyers, reflecting diversification in food type and customer base.

Cost management was a priority with a 23% reduction in general and administrative expenses and a 65% decrease in R&D spending due to reallocating resources towards commercial operations.

The company secured a $6.9 million private placement of convertible notes, with $4 million closed in fiscal 2026, demonstrating strong insider support and confidence in future growth.

Burcon expressed a positive future outlook, expecting significant revenue growth in fiscal 2027 and aiming for $10 million in sales by calendar 2026, with a pathway to positive cash flow.

Full Transcript OPERATOR Good afternoon, everyone, and thank you for participating in today's conference call to discuss Burcon NutraScience Corporation's fiscal 2026 results, year ended March 31, 2026.

Joining us today are Keith Underwood, Burcon's Chief Executive Officer, and Alex Varty, the company's Interim Chief Financial Officer.

Following their presentation, we will open up the call for your questions.

To join the question queue, you may press star then one on your telephone keypad.

Should you need assistance during the conference call, you may signal an operator by pressing star then zero.

Before we conclude today's call, I'll provide the company's safe harbor statement with the important cautions regarding the forward-looking statements made during this call.

Now I would like to turn the call over to the CEO of Burcon, Mr.

Keith Underwood.

Sir, please go ahead.

Kip Underwood, Chief Executive Officer Thank you, operator.

And good morning, good afternoon, good evening to those attending the call today.

We very much appreciate you taking time out of your day to spend time with us.

We want you all to have three takeaways from today's presentation.

The first is that we are targeting a large growing market.

The second, that our technology platform delivers highly differentiated products.

I think three, maybe most importantly, is throughout fiscal 2026, we are delivering on commercial success.

Before we get into fiscal 2026, I want to take a step back and kind of go through a couple of key points as to why we are so excited about the opportunity in front of us.

The first, as I think many of you can probably see, protein is everywhere.

If you've been in a grocery store, you've read a newspaper, you've seen a commercial on television or streaming, protein is hot.

Any consumer brand product that has a positioning on the front panel, 20 grams of protein, 30 grams of protein, 10 grams of protein per serving.

Those types of consumer products are bullseyes for Burcon's technology.

That is where we are, in fact, the most relevant, so tremendously exciting market.

Protein is everywhere and it's not just a fad.

So there's some fundamental drivers at the consumer level that are driving protein demand and the opportunity for us.

The first and foremost is people seeking better nutrition.

What is accelerating the protein growth beyond better nutrition is GLP1 or weight loss medication.

When people are on this medication, which is growing rapidly, they need more protein on fewer calories.